In particular, targeting of the programmed death-1 (PD-1) and the programmed death-ligand-1 (PD-L1) has shown considerable anti-tumor activity across multiple cancer entities including non-small cell lung cancer [1–3]. Here, CD274 is linked to neoplasm.